HealthcareServices

Benign Prostatic Hyperplasia Treatment Market Forecast 2026–2035: How to Leverage Market Growth

February 20, 2026February 20, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the benign prostatic hyperplasia treatment market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the Benign Prostatic Hyperplasia Treatment Market expected to reach by 2030?

The benign prostatic hyperplasia treatment market size has demonstrated significant growth in the past few years. Projections indicate it will expand from $8.69 billion in 2025 to reach $9.17 billion by 2026, advancing at a compound annual growth rate (CAGR) of 5.6%. This historical growth is attributable to factors such as an increasing aging male population, a rising prevalence of urinary disorders, the expansion of urology specialty services, the growing use of pharmacological treatments, and improved access to diagnostic screening.

The benign prostatic hyperplasia treatment market size is projected to experience substantial expansion in the coming years, reaching $11.29 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing embrace of robotic-assisted prostate procedures, a heightened emphasis on personalized treatment strategies, the expansion of therapy choices available at home, the growing incorporation of digital patient monitoring tools, and an increasing need for minimally invasive interventions. Key trends expected over the forecast period encompass a greater adoption of minimally invasive surgical methods, a surging demand for targeted drug therapies, an increasing application of combination treatment protocols, the expansion of treatment options in outpatient settings, and an intensified focus on managing symptoms and improving patients’ quality of life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21112&type=smp

What Drivers Are Driving Adoption Within The Benign Prostatic Hyperplasia Treatment Market?

The increasing acceptance of minimally invasive surgeries is anticipated to propel the growth of the benign prostatic hyperplasia treatment market in the coming years. Minimally invasive surgeries are procedures characterized by small or no incisions, employing specialized instruments to minimize recovery time, pain, and the risk of complications. This rise in adoption is driven by benefits like shorter recovery periods, reduced discomfort, lower chances of complications, and improved cosmetic outcomes. For benign prostatic hyperplasia treatment, minimally invasive surgeries offer patients quicker recovery times, reduced risks of complications, and effective symptom relief, leading to enhanced overall surgical results. For example, in September 2023, the American Society of Plastic Surgeons (ASPS), a U.S.-based professional association, reported that nearly 25.4 million minimally invasive cosmetic procedures were performed in 2023, which was up 7% from 23.7 million in 2022. Consequently, the growing adoption of minimally invasive surgeries is fueling the expansion of the benign prostatic hyperplasia treatment market.

How Is The Benign Prostatic Hyperplasia Treatment Market Organized Into Various Segments?

The benign prostatic hyperplasia treatment market covered in this report is segmented –

1) By Treatment: Minimal Invasive Surgery, Invasive Surgery

2) By Therapeutic Class: Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Other Therapeutic classes

3) By End User: Home Healthcare, Hospitals And Clinics

Subsegments:

1) By Minimal Invasive Surgery: Transurethral Resection of the Prostate (TURP), Laser Surgery, Prostatic Urethral Lift, Transurethral Incision of the Prostate (TUIP), Microwave Therapy

2) By Invasive Surgery: Open Prostatectomy, Robotic Prostatectomy

Which Trends Are Guiding The Evolution Of The Benign Prostatic Hyperplasia Treatment Market?

Leading firms in the benign prostatic hyperplasia treatment market are concentrating on creating novel therapies, like intraprostatic drug elution therapy, to secure a competitive edge. This therapy entails inserting a bioabsorbable implant directly into the prostate gland for the sustained, localized delivery of a therapeutic substance. For example, in May 2025, Resurge Therapeutics, a US-based developer of urology technology, unveiled a paclitaxel-eluting bioabsorbable implant designed for BPH, which provides convenient office-based administration, precise drug delivery, and reduced post-procedure discomfort. Such localized administration minimizes systemic exposure, improves effectiveness, and helps maintain sexual function. Nevertheless, its long-term safety profile and widespread adoption are still being assessed.

Who Are The Prominent Global Companies Shaping The Benign Prostatic Hyperplasia Treatment Market Landscape?

Major companies operating in the benign prostatic hyperplasia treatment market are Astellas Pharma Inc., Bayer AG, Pfizer Inc., Merck & Co Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sanofi S.A., Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated, Cook Medical Incorporated, Coloplast Group, Medtronic Public Limited Company, Urovant Sciences Ltd., UroGen Pharma Ltd., Urologix Inc., Zenflow Inc., HistoSonics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/benign-prostatic-hyperplasia-treatment-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Benign Prostatic Hyperplasia Treatment Market?

North America was the largest region in the benign prostatic hyperplasia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the benign prostatic hyperplasia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Benign Prostatic Hyperplasia Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21112&type=smp

Browse Through More Reports Similar to the Global Benign Prostatic Hyperplasia Treatment Market 2026, By The Business Research Company

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-nuclear-medicine-diagnostics-global-market-report

Drugs For Benign Prostatic Hypertrophy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795